The role of interoception and alliesthesia in addiction.
This review presents a novel conceptualization of addiction, integrating the concepts of interoception (i.e., the CNS representation of visceral feelings) and alliesthesia (i.e., that rewarding properties of stimuli are dependent on the internal state of the individual) with existing theories. It is argued that the body state, as defined by the integration of interoceptive information, is a crucial arbiter of the risk for initiation of and transition to compulsive use of addictive compounds. Overall, individuals at risk for drug dependence are characterized by an altered internal bodily state that leads to a change in hedonic and incentive motivational properties of addictive drugs. Specifically, drug dependent individuals experience alliesthesia of interoceptive processing, leading to increased incentive motivational properties of the drug over time and thereby increasing the probability of subsequent use. This extension of previous theories of addiction to include interoception and alliesthesia is based upon a clearly delineated set of neural substrates mediating interoception, key elements of which also recently have been implicated in drug addiction. The model thereby provides new potential targets for interventions that are aimed at changing the internal state that puts the individual at risk for continued substance use.
Paulus
Martin P
MP
Department of Psychiatry, University of California, San Diego, CA 92037, USA. mpaulus@ucsd.edu
Tapert
Susan F
SF
Schulteis
Gery
G
D000818:Animals; D002490:Central Nervous System / Q000503:physiopathology*; D004644:Emotions; D006801:Humans; D008954:Models, Biological; D009042:Motivation; D010465:Perception / Q000502:physiology*; D057181:Pleasure; D012201:Reward; D012677:Sensation / Q000502:physiology; D019966:Substance-Related Disorders / Q000503:physiopathology* / Q000523:psychology
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3137-46
18640920
Annu Rev Neurosci. 2000;23:473-500
10845072
J Neurosci. 2005 Dec 14;25(50):11757-67
16354934
J Comp Neurol. 1982 Nov 20;212(1):38-52
7174907
Science. 1978 Jul 21;201(4352):262-4
566469
Nat Neurosci. 2005 Nov;8(11):1481-9
16251991
Nat Neurosci. 2008 Apr;11(4):389-97
18368045
Alcohol Clin Exp Res. 2008 Jun;32(6):1096-104
18445111
Annu Rev Psychol. 2008;59:29-53
18154498
Psychopharmacology (Berl). 2005 Dec;183(2):171-80
16163517
Science. 2007 Oct 26;318(5850):655-8
17962567
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3125-35
18640910
Neurobiol Learn Mem. 1997 Jan;67(1):57-63
9013501
Brain Res Brain Res Rev. 2001 Oct;36(2-3):129-38
11690609
Nature. 2003 Jul 17;424(6946):316-20
12867983
Nature. 1999 Apr 15;398(6728):567-70
10217139
Dialogues Clin Neurosci. 2007;9(4):379-87
18286798
BMC Psychiatry. 2002 May 29;2:7
12036434
J Comp Neurol. 2005 Sep 19;490(2):101-18
16052493
Nat Neurosci. 2004 Feb;7(2):189-95
14730305
Neuron. 2009 Feb 12;61(3):481-90
19217383
J Abnorm Psychol. 2008 May;117(2):467-72
18489224
Cereb Cortex. 2000 Mar;10(3):206-19
10731217
Anat Rec A Discov Mol Cell Evol Biol. 2004 Nov;281(1):1212-25
15470678
Science. 2007 Jan 26;315(5811):531-4
17255515
Neuron. 2007 Apr 19;54(2):183-6
17442239
Science. 1971 Sep 17;173(4002):1103-7
5098954
Neuron. 2008 Jul 10;59(1):11-34
18614026
Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):377-93
17169534
Biol Psychiatry. 2006 Aug 15;60(4):383-7
16780813
Am Psychol. 1980 Aug;35(8):691-712
7416563
Nature. 2006 Feb 16;439(7078):865-70
16482160
Alcohol Res Health. 1999;23(3):215-24
10890817
Science. 2003 Oct 10;302(5643):290-2
14551436
Science. 1998 May 1;280(5364):747-9
9563953
Neurosci Lett. 2000 Jul 14;288(2):159-62
10876085
Addiction. 1996 Jul;91(7):921-49; discussion 951-65
8688822
Nat Rev Neurosci. 2005 Sep;6(9):691-702
16136173
J Comp Neurol. 2004 Jan 12;468(3):425-40
14681935
Psychol Rev. 2004 Jan;111(1):33-51
14756584
Brain Res. 2004 Mar 12;1000(1-2):78-84
15053955
Appetite. 2007 Mar;48(2):139-44
17034902
Nat Neurosci. 2005 Nov;8(11):1458-63
16251988
Alcohol Res Health. 1999;23(3):197-206
10890815
Ann N Y Acad Sci. 1998 May 1;840:33-44
9629234
Exp Clin Psychopharmacol. 2001 Feb;9(1):3-13
11519632
Nat Rev Neurosci. 2009 Jan;10(1):59-70
19096369
Physiol Behav. 1994 Jan;55(1):169-73
8140163
Lung. 2008;186 Suppl 1:S107-11
17952695
Neurotox Res. 2008 Oct;14(2-3):169-83
19073424
Trends Cogn Sci. 2004 Dec;8(12):539-46
15556023
Behav Brain Sci. 2008 Aug;31(4):415-37; discussion 437-87
18662461
Science. 2005 Feb 18;307(5712):1118-21
15718473
Trends Neurosci. 2009 Jan;32(1):56-67
18986715
Psychol Rev. 1974 Mar;81(2):119-45
4817611
Philos Trans R Soc Lond B Biol Sci. 2005 Apr 29;360(1456):797-814
15937013
Physiol Behav. 1999 Sep;67(3):409-15
10497960
Neuropharmacology. 2009;56 Suppl 1:48-62
18722390
Addiction. 2004 Dec;99(12):1542-7
15585045
Brain. 2001 Sep;124(Pt 9):1720-33
11522575
Neuroimage. 2002 Jun;16(2):331-48
12030820
Brain Res Brain Res Rev. 1996 Oct;22(3):229-44
8957561
Addiction. 2005 Mar;100(3):387-96
15733252
Addiction. 2004 Jun;99 Suppl 1:5-29
15128378
Science. 1997 Oct 3;278(5335):52-8
9311926
Nebr Symp Motiv. 1986;34:257-323
3627296
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761
Recent Dev Alcohol. 1998;14:177-95
9751946